Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704105 | 0.90 | KIF11 (0.38) | ALDH1A1L3MBTL1NR3C2CTNNB1WNT3A | |
| SCHEMBL136228 | 0.84 | CA1 (0.46) | ALDH1A1L3MBTL1NR3C2HTTMEN1 | |
| SCHEMBL2494552 | 0.84 | KIF11 (0.42) | ALDH1A1L3MBTL1NR3C2CTNNB1WNT3A | |
| SCHEMBL992027 | 0.84 | KIF11 (0.42) | ALDH1A1L3MBTL1NR3C2CTNNB1WNT3A | |
| SCHEMBL2288429 | 0.81 | NR3C2 (0.33) | ALDH1A1L3MBTL1NR3C2CTNNB1WNT3A | |
| SCHEMBL3022976 | 0.81 | CA1 (0.46) | ALDH1A1L3MBTL1NR3C2HTTMEN1 | |
| SCHEMBL2491447 | 0.78 | KIF11 (0.40) | ALDH1A1NR3C2HTTLMNAHSD17B10 | |
| SCHEMBL4194075 | 0.78 | LMNA (0.40) | ALDH1A1L3MBTL1NR3C2HTTLMNA | |
| SCHEMBL2491593 | 0.77 | CA1 (0.41) | ALDH1A1L3MBTL1CTNNB1WNT3ALMNA | |
| SCHEMBL15841458 | 0.76 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1NR3C2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071737-B2 | Nucleic acid ligand complexes | Glead Sciences, Inc. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-2168973-A1 | Nucleic acid ligand complexes | Gilead Sciences, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-0824541-B1 | NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-0824541-A4 | NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20050164974-A1 | Nucleic acid ligand complexes | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20030125263-A1 | Nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2003-07-03 | — | — | US | disclosed |
| US-6465188-B1 | PARTITIONING, GENETIC REPLICATION; SELEX | GILEAD SCIENCES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6147204-A | COMPLEX FOR TARGETING THERAPEUTIC OR DIAGNOSTIC AGENTS TO PREFERENTIAL BIOLOGICAL TARGET | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6011020-A | THERAPEUTIC OR DIAGNOSTIC COMPLEX COMPRISED OF A NUCLEIC ACID LIGAND AND A POLYETHYLENE GLYCOL (PEG), WHEREIN SAID NUCLEIC ACID LIGAND IS COVALENTLY LINKED TO SAID PEG | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0824541-A1 | NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996034876-A1 | NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | TLR9, SNRPE, HAVCR2 | ALDH1A1 3617/4885L3MBTL1 410/4885NR3C2 1980/4885 |
| US-20050164974-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | ALDH1A1 3617/4885L3MBTL1 410/4885NR3C2 1980/4885 |
| US-20030125263-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | ALDH1A1 3617/4885L3MBTL1 410/4885NR3C2 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.